HK Stock Market Move | EVEREST MED (01952) surged over 6% in early trading. EVM14 addresses the clinical pain points of squamous cell carcinoma treatment and leads the way in clinical development progress.

EVEREST MED (01952) rose more than 6% in the morning session, as of the time of publication, it rose 6.66% to 54.45 Hong Kong dollars, with a turnover of 142 million Hong Kong dollars. On the news front, according to EVEREST MED's official WeChat account, on October 14th, the company announced that its universal live tumor therapy vaccine EVM14 injection had enrolled its first patient in a global multi-center Phase I clinical trial at the clinical research institution NEXT Oncology Virginia in the United States. This is an important clinical advancement following the approval of the IND application for EVM14 clinical trials by the U.S. Food and Drug Administration (FDA) and the China National Medical Products Administration (NMPA). The article "EVEREST MED (01952) mRNA tumor vaccine EVM14 breaks through consecutively: China approved for clinical trial, first patient enrolled in Phase I in the U.S." points out that the development of EVM14 is directly addressing the clinical pain points in current squamous cell carcinoma treatment. Currently, the population of squamous cell carcinoma patients is large, but existing standard treatments have not yet achieved satisfactory results, resulting in significant unmet medical needs. As a universal live tumor vaccine, EVM14 has advantages such as no need for HLA screening, availability for immediate delivery, lower production costs, and applicability to multiple tumor types, showing broad prospects in the field of tumor treatment. It is predicted that the mRNA tumor vaccine market could reach 40.651 billion U.S. dollars under a neutral scenario, with universal vaccines dominating due to cost advantages. With its differentiation advantage, EVM14 has been leading the clinical development process in the competitive industry.